作　　者： (石勇铨）; (李焱）;

机构地区： 上海长征医院内分泌科,200003

出　　处： 《中华内分泌代谢杂志》 2017年第8期705-708,共4页

摘　　要： 我国糖尿病前期患病率逐年猛增，在冠心病、高血压等人群中糖代谢异常的患病率更高。糖尿病可防可控。既往研究证实生活方式干预和药物干预可以延缓糖尿病前期人群进展为糖尿病，且阿卡波糖可用于糖耐量受损（IGT）及糖尿病患者的心血管一级预防，但药物干预对于IGT患者的心血管二级预防是否有获益尚无定论。阿卡波糖心血管评估（ACE）是在中国人群中进行的一项多中心、随机、安慰剂对照、双盲研究，其目的在于评估使用阿卡波糖能否减少合并IGT的冠心病患者的心血管事件风险及新发糖尿病风险，其结果对于中国糖尿病防治具有重要的意义和价值。本文回顾既往的循征证据，并对ACE研究结果做出预测。 The prevalence of prediabetes is increasing rapidly in China, and with higher prevalence in coronary heart disease and hypertension patients. Diabetes can be controlled and prevented, previous studies have confirmed that lifestyle interventions and drug interventions can delay the progression of prediabetes to diabetes, and acarbose can be used for the primary prevention of cardiovascular events in impaired glucose tolerance （ IGT ） and diabetic patients, but benefits of drug intervention for secondary prevention of cardiovascular disease in IGT population are uncertain. The Acarbose Cardiovascular Evaluation （ACE） Study is a muhicentre, randomized, placebo-controlled, double-blind study, with the aim of assessing the use of acarbose to reduce the risk of cardiovascular events and the onset of diabetes in IGT patients with cardiovascular disease in China , the results will be very meaningful and valuable for the prevention and treatment of diabetes. We will predict the results of ACE Study based on previous evidences.

关 键 词： 阿卡波糖 糖尿病前期 心血管结局